To include your compound in the COVID-19 Resource Center, submit it here.

Synagis palivizumab: Phase IV data; marketed

In an outcomes survey of 2,116 patients treated with monthly injections of Synagis

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE